Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
about
Diffusion-Weighted Magnetic Resonance Imaging Reversal by Gene Knockdown of Matrix Metalloproteinase-9 Activities in Live Animal BrainsDJ-1 cleavage by matrix metalloproteinase 3 mediates oxidative stress-induced dopaminergic cell deathImplications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic StrokeA Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral IschemiaRational modulation of the innate immune system for neuroprotection in ischemic strokeSelective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injuryGlyburide is associated with attenuated vasogenic edema in stroke patients.Neuroprotective effects of lipoxin A4 in central nervous system pathologies.Variants of the Matrix Metalloproteinase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke.Mmp-9, a potential target for cerebral ischemic treatment.Cardiac aging is initiated by matrix metalloproteinase-9-mediated endothelial dysfunction.Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9.Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activatorAssociation of matrix metalloproteinases with MRI indices of brain ischemia and agingPlasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?Infrared optical imaging of matrix metalloproteinases (MMPs) up regulation following ischemia reperfusion is ameliorated by hypothermia.The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia.General versus specific actions of mild-moderate hypothermia in attenuating cerebral ischemic damage.Comprehensive gene expression profiling reveals synergistic functional networks in cerebral vessels after hypertension or hypercholesterolemia.Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice.GABA receptors ameliorate Hcy-mediated integrin shedding and constrictive collagen remodeling in microvascular endothelial cells.Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarctionSex-independent neuroprotection with minocycline after experimental thromboembolic stroke.The complexity of tissue-type plasminogen activator: can serine protease inhibitors help in stroke management?The axon-glia unit in white matter stroke: mechanisms of damage and recovery.Extracellular proteolytic pathophysiology in the neurovascular unit after stroke.Endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology.The inhibitory effect of S-nitrosoglutathione on blood-brain barrier disruption and peroxynitrite formation in a rat model of experimental strokeInhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia.Association of dimethylarginines and mediators of inflammation after acute ischemic strokeProtein therapeutics: new applications for pharmacogenetics.Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocyclineMatrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke.Advances in hemorrhagic stroke therapy: conventional and novel approaches.Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats.Circulating matrix metalloproteinases in children with diabetic ketoacidosis.Matrix metalloproteinases: drug targets for myocardial infarction.Post-ischemic brain damage: pathophysiology and role of inflammatory mediators.Matrix metalloproteinase-9: Many shades of function in cardiovascular disease.Mmp-9 inhibition: a therapeutic strategy in ischemic stroke.
P2860
Q22065143-0F97E2BE-111B-4C52-A829-B795F2E22DCFQ24304197-98AF534B-3C68-4910-93DD-D43E41F0F440Q26766038-39FF0DD2-6B12-4FFA-8845-0ED3DD568FACQ26772837-31C974C5-6BAA-4E51-B5B4-6250D4374862Q26851831-EAC15486-DCEF-40FA-801C-F909DFB0466BQ28534597-20D0632D-81CC-455B-88E8-A6BED458B794Q30670386-67ACBACB-D1F9-43A7-AFDB-478107D78B93Q30857083-D080EA33-C876-439F-8C16-16E36CB5C293Q33539984-CA65B2F3-621B-4F23-AC20-31B4915FD78EQ33612510-8AF0C3A6-556F-48BA-A9BC-C7FB55ECAC65Q33626536-F828F140-1F9F-49CB-B610-DBC70C641CCFQ33684529-F1AB70B1-CC18-4B87-8E03-5AF00AFC2C34Q33823616-565FDB26-5C36-45FF-B05C-6EBD15604DF2Q33936858-AC1508FD-75AC-4F3B-8205-26B515D80D36Q34018715-118DE530-6E52-4491-BE1C-6FA2E6BEC634Q34319977-A1A6BAB1-1FD1-4FA0-ACD0-E9626C63E943Q34335614-0DFB7AEF-66F2-4C15-81A7-92660525D171Q34660713-69037757-38BA-4846-8B2D-D6B9BA790B48Q34848063-4D0837AC-62ED-403E-9134-320B516FF1D2Q35014025-F36C7F8C-8593-4289-9DD0-90B528679F2BQ35238742-BD18CB3E-8912-4F29-81BB-03C3FB0BC175Q35688512-8742AB4C-8028-4B60-8544-7922A7B4746EQ35779826-3B8AFB43-1785-4336-9474-D3A724C8D5ACQ35842504-C4C0C10E-759D-4966-9E70-2BEABF764E71Q35984483-CB2E2E9E-246E-4A78-8657-0586C23158F5Q36052713-73E19426-7308-4A6F-B44B-1ADC88BA3B6EQ36072867-D70ED5D9-AAA2-46A7-B50C-0BEDC1A684EAQ36347434-8ACA5D6F-E958-4395-BFA5-50A423029DD2Q36405496-86D7F7F0-72A5-4B35-BC2A-004B07828BDFQ36498512-32192247-2EB0-4BD0-8BDE-2F7E90307316Q36501235-229CCF79-2310-4B26-A750-016A343F3AD0Q36514428-2A88E143-21E7-419B-8BBA-DBBDBFD308A4Q36736442-1E6756C0-43FF-44A5-8CA4-76A24F9A7481Q36944012-A5347795-BBB3-48CC-B3D0-139747EEA6D8Q37017515-F5005CCD-930F-427F-B548-AA07140B18E7Q37153161-52ED8FA4-F83D-4D5F-8084-95250ED38C93Q37308645-5AFFA627-3910-4304-B99B-33D5458FE3BBQ37352179-CD1286C4-1BD7-45D2-9B96-237D0267B973Q37380847-A42603F5-6DFC-41EA-8673-7F5A58EBBB05Q37568882-00B0EB9C-612E-4333-A1D8-DCA045A96AD2
P2860
Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Profiles of matrix metalloprot ...... luence of different therapies.
@en
type
label
Profiles of matrix metalloprot ...... luence of different therapies.
@en
prefLabel
Profiles of matrix metalloprot ...... luence of different therapies.
@en
P2093
P1433
P1476
Profiles of matrix metalloprot ...... luence of different therapies.
@en
P2093
Humphrey Gardner
James Koziol
Pamela Kalb
Simone Wagner
Solveig Horstmann
P304
P356
10.1161/01.STR.0000088062.86084.F2
P407
P577
2003-08-07T00:00:00Z